Evaluation of the levels of fibroblast growth factor (FGF-23) and inflammation markers in patients with type 2 diabetes mellitus and different stages of chronic kidney disease
Автор: Vasilkova V.M., Mokhort T.V., Bayrasheva V.K., Korotaeva L.E., Yarets Yu. I., Shestovets O.N., Borovets Ya. A., Naumenko E.P.
Журнал: Juvenis scientia @jscientia
Рубрика: Оригинальное исследование
Статья в выпуске: 2 т.6, 2020 года.
Recently, inflammatory and regulatory mechanisms that are involved in the onset and progression of angiopathies in diabetes mellitus (DM), including diabetic kidney disease (DKD), have been studied. In this study, we assessed the levels of fibroblast growth factor-23 (FGF-23) and inflammatory markers in patients with type 2 DM and different stages of chronic kidney disease (CKD). We investigated 64 patients with type 2 DM aged 34-84 years. The results showed significant changes in the levels of FGF-23, tumour necrosis factor alpha (TNF-alpha), C-reactive protein (CRP), high-sensitivity C-reactive protein (hsCRP), and interleukin-6 (IL-6) with the progression of CKD in patients with type 2 diabetes. Multiple regression analysis demonstrated the presence of an independent interconnection between serum levels of FGF-23 and creatinine.
Diabetes mellitus, diabetic kidney disease, fibroblast growth factor-23, cytokines, inflammation
Короткий адрес: https://sciup.org/14115955